This sort of comment is so useless.
Do you actually believe cancer treatments are what the EU is going to lose on with these regulations?
Why?
Do you actually believe cancer treatments are what the EU is going to lose on with these regulations?
Why?
1. If the AI is more effective at finding successful cancer treatment for Little Endians versus Big Endians, then there is a non-zero chance that the AI will be deemed discriminatory. This could play out in a number of ways, but restricted access is certainly one of them. I live in California, and I also think that there is a non-zero chance of this happening here. It all depends on how the treatment and data are presented.
2. If the manufacturer of said treatment is anti-union, will the treatment options be distributable in certain parts of Europe?
As is yours.
Who said anything about where I think this AI would be developed?
US is possible. So is China. So is Europe. Not necessarily in that order. Japan might have an outside chance if certain things line up a certain way.
If Europe and the US make AI research overly cumbersome, I’m sure there are plenty of countries that will offer sweetheart deals to the best teams looking for a new home.
"Drugmakers Boehringer-Ingelheim and Eli Lilly have called off plans to market their Type 2 diabetes drug linagliptin in Germany because new legislation in the country could mean that pill's price could end up being too low."
https://www.reuters.com/article/boehringer-lilly-idINL5E7K23...